Objective: To evaluate preclinical antipsychotic properties of M4 agonism while minimizing offtarget side effects using the novel M4 full agonist CV-0000042 and novel M4 partial agonist CV-0000071.
Objective: To evaluate preclinical antipsychotic properties of M4 agonism while minimizing offtarget side effects using the novel M4 full agonist CV-0000042 and novel M4 partial agonist CV-0000071.
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.